Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-36.63m
- Incorporated2020
- Employees10.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mural Oncology PLC | 0.00 | -207.45m | 65.83m | 117.00 | -- | 0.2461 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 66.07m | 230.00 | -- | -- | -- | 1.34 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Medicinova Inc | 1.00m | -8.57m | 66.21m | 13.00 | -- | 1.06 | -- | 66.21 | -0.1748 | -0.1748 | 0.0204 | 1.27 | 0.0142 | -- | -- | 76,923.08 | -12.21 | -15.36 | -12.80 | -15.90 | -- | -- | -857.15 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 67.92m | 31.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Atara Biotherapeutics Inc | 8.57m | -276.13m | 68.10m | 225.00 | -- | -- | -- | 7.94 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 68.36m | 9.00 | -- | 3.49 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 68.65m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| Landos Biopharma Inc | 0.00 | -21.94m | 69.41m | 19.00 | -- | 2.18 | -- | -- | -3.49 | -3.49 | 0.00 | 10.20 | 0.00 | -- | -- | 0.00 | -52.67 | -59.84 | -61.86 | -72.15 | -- | -- | -- | -795.80 | -- | -516.52 | 0.00 | -- | -- | -- | 44.15 | -- | -- | -- |
| SCYNEXIS Inc | 140.14m | 67.04m | 69.51m | 29.00 | 1.42 | 0.9383 | -- | 0.496 | 1.29 | 1.29 | 2.90 | 1.96 | 1.30 | 34.76 | 133.41 | 4,832,483.00 | 62.01 | -30.02 | 73.55 | -36.35 | 88.85 | -- | 47.84 | -86.76 | 6.26 | 33.49 | 0.1428 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -15.96m | 69.72m | 21.00 | -- | 1.70 | -- | -- | -1.47 | -1.47 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -31.15 | -28.83 | -32.91 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Rallybio Corp | 0.00 | -74.56m | 69.95m | 43.00 | -- | 0.6591 | -- | -- | -1.84 | -1.84 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -50.37 | -- | -54.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Assembly Biosciences Inc | 7.16m | -61.23m | 70.45m | 65.00 | -- | 1.71 | -- | 9.84 | -14.02 | -14.02 | 1.63 | 7.50 | 0.06 | -- | 14.51 | 110,200.00 | -51.32 | -39.69 | -66.88 | -44.03 | -- | -- | -854.78 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Elutia Inc | 24.75m | -41.25m | 71.10m | 54.00 | -- | -- | -- | 2.87 | -2.20 | -2.08 | 1.35 | -1.66 | 0.4408 | 1.97 | 4.90 | 458,240.80 | -73.48 | -42.93 | -309.94 | -79.34 | 44.67 | 43.32 | -166.70 | -64.16 | 0.6367 | -3.54 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 31 Dec 2023 | 3.88m | 10.43% |
| Ikarian Capital LLCas of 31 Dec 2023 | 257.98k | 0.69% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 242.17k | 0.65% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 202.54k | 0.55% |
| Geode Capital Management LLCas of 31 Dec 2023 | 172.25k | 0.46% |
| Lumyna Investments Ltd.as of 30 Sep 2022 | 166.62k | 0.45% |
| Formidable Asset Management LLCas of 31 Dec 2023 | 58.19k | 0.16% |
| Boothbay Fund Management LLCas of 31 Dec 2023 | 55.06k | 0.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 41.73k | 0.11% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 23.35k | 0.06% |
